WO2004033722A3 - Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes - Google Patents

Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes Download PDF

Info

Publication number
WO2004033722A3
WO2004033722A3 PCT/GB2003/004051 GB0304051W WO2004033722A3 WO 2004033722 A3 WO2004033722 A3 WO 2004033722A3 GB 0304051 W GB0304051 W GB 0304051W WO 2004033722 A3 WO2004033722 A3 WO 2004033722A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
adme
metabolism
probes
elimination
Prior art date
Application number
PCT/GB2003/004051
Other languages
French (fr)
Other versions
WO2004033722A2 (en
Inventor
Gareth Wyn Roberts
Keith Grimaldi
Original Assignee
Sciona Ltd
Gareth Wyn Roberts
Keith Grimaldi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciona Ltd, Gareth Wyn Roberts, Keith Grimaldi filed Critical Sciona Ltd
Priority to AU2003269159A priority Critical patent/AU2003269159A1/en
Publication of WO2004033722A2 publication Critical patent/WO2004033722A2/en
Publication of WO2004033722A3 publication Critical patent/WO2004033722A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

According to the invention, the number of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide critical clinical information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies which comprises of the identification of the core group of genes and their sequence variants required to provide a broad base of clinical prognostic information ” genostics ”. The invention is meant to radically enhance the ability of clinicians, healthcare professionals and other parties to plan and manage healthcare provision and the targeting of appropriate healthcare resources to those deemed most in need.
PCT/GB2003/004051 2002-09-23 2003-09-23 Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes WO2004033722A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003269159A AU2003269159A1 (en) 2002-09-23 2003-09-23 Genetic profiling and healthcare management: adme (absorption, distribution, metabolism and elimination) and toxicology related genes and probes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0222042.4 2002-09-23
GBGB0222042.4A GB0222042D0 (en) 2002-09-23 2002-09-23 Genostics

Publications (2)

Publication Number Publication Date
WO2004033722A2 WO2004033722A2 (en) 2004-04-22
WO2004033722A3 true WO2004033722A3 (en) 2004-08-12

Family

ID=9944593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004051 WO2004033722A2 (en) 2002-09-23 2003-09-23 Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes

Country Status (3)

Country Link
AU (1) AU2003269159A1 (en)
GB (1) GB0222042D0 (en)
WO (1) WO2004033722A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789588A1 (en) * 2004-09-06 2007-05-30 Medizinische Hochschule Hannover Methods and its kits based on ugt1a7 promoter polymorphism
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
JP4410269B2 (en) * 2007-03-28 2010-02-03 株式会社東芝 Nucleic acid primer set, kit for detecting genotype of N-acetyltransferase 2 (NAT2), and detection method using the primer set
WO2009052559A1 (en) * 2007-10-22 2009-04-30 Melbourne Health A diagnostic assay
US7972793B2 (en) 2009-11-04 2011-07-05 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7985551B2 (en) 2009-11-04 2011-07-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7951543B2 (en) 2009-11-04 2011-05-31 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7951542B2 (en) 2009-11-04 2011-05-31 Surgene, LLC Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US10210312B2 (en) 2013-02-03 2019-02-19 Youscript Inc. Systems and methods for quantification and presentation of medical risk arising from unknown factors
CN109355368A (en) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 A kind of kit and method of quick detection hypertension individuation medication gene pleiomorphism

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2339200A (en) * 1998-06-06 2000-01-19 Genostic Pharma Ltd Genomic profiling of disease susceptibility

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2339200A (en) * 1998-06-06 2000-01-19 Genostic Pharma Ltd Genomic profiling of disease susceptibility

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BIGLER J ET AL: "CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.", CANCER RESEARCH. UNITED STATES 1 MAY 2001, vol. 61, no. 9, 1 May 2001 (2001-05-01), pages 3566 - 3569, XP002284193, ISSN: 0008-5472 *
BULLETIN OF NATIONAL INSTITUTE OF HEALTH SCIENCES 1998 JAPAN, no. 116, 1998, pages 69 - 81, ISSN: 1343-4292 *
BUTLER W J ET AL: "Metabolic genotypes and risk for colorectal cancer.", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. AUSTRALIA JUN 2001, vol. 16, no. 6, June 2001 (2001-06-01), pages 631 - 635, XP002284253, ISSN: 0815-9319 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2001 (2001-12-01), RISCH ANGELA ET AL: "Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas", XP002284256, Database accession no. PREV200200096544 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, OZAWA S: "Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes", XP002284255, Database accession no. EMB-1999021735 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1998 (1998-02-01), YAMAZAKI H ET AL: "Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.", XP002284194, Database accession no. NLM9522436 *
ERICKSON R P ET AL: "Genetic variation in beta-adrenergic receptors and their relationship to susceptibility for asthma and therapeutic response.", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS. UNITED STATES APR 2001, vol. 29, no. 4 Pt 2, April 2001 (2001-04-01), pages 557 - 561, XP002284264, ISSN: 0090-9556 *
EVANS WILLIAM E ET AL: "Pharmacogenomics: Translating functional genomics into rational therapeutics", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 487 - 491, XP002193947, ISSN: 0036-8075 *
INGELMAN-SUNDBERG M ET AL: "Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment", TRENDS IN PHARMACOLOGICAL SCIENCES 1999 UNITED KINGDOM, vol. 20, no. 8, 1999, pages 342 - 349, XP002284252, ISSN: 0165-6147 *
MITRUNEN KATJA ET AL: "Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer", CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 10, no. 3, March 2001 (2001-03-01), pages 229 - 236, XP002284254, ISSN: 1055-9965 *
PHARMACOGENETICS, vol. 11, no. 9, December 2001 (2001-12-01), pages 757 - 764, ISSN: 0960-314X *
STEWARD D J ET AL: "GENETIC ASSOCIATION BETWEEN SENSITIVITY TO WARFARIN AND EXPRESSION OF CYP2C9*3", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 7, no. 5, October 1997 (1997-10-01), pages 361 - 367, XP000921131, ISSN: 0960-314X *
XENOBIOTICA;THE FATE OF FOREIGN COMPOUNDS IN BIOLOGICAL SYSTEMS. ENGLAND FEB 1998, vol. 28, no. 2, February 1998 (1998-02-01), pages 103 - 115, ISSN: 0049-8254 *

Also Published As

Publication number Publication date
GB0222042D0 (en) 2002-10-30
AU2003269159A8 (en) 2004-05-04
WO2004033722A2 (en) 2004-04-22
AU2003269159A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
Gullapalli et al. Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics
van der Weide et al. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology
Jang et al. Polymorphisms in the Matrilin-1 gene and risk of mandibular prognathism in Koreans
Denisova et al. Frequent DPH3 promoter mutations in skin cancers
Papagerakis et al. Premature stop codon in MMP20 causing amelogenesis imperfecta
Enoch et al. ‘Young’oral fibroblasts are geno/phenotypically distinct
US20160068904A1 (en) Methods of skin analysis and uses thereof
WO2004033722A3 (en) Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes
Heilmann et al. Evidence for a polygenic contribution to androgenetic alopecia
Knudsen et al. Increased skewing of X chromosome inactivation with age in both blood and buccal cells
Zschiedrich et al. MDR1 variants and risk of Parkinson disease: association with pesticide exposure?
Perls Centenarians who avoid dementia
Prata et al. Association of DAO and G72 (DAOA)/G30 genes with bipolar affective disorder
WO2003010336A3 (en) Molecular markers for hepatocellular carcinoma
Wang et al. Association between polymorphisms of the insulin-degrading enzyme gene and late-onset Alzheimer disease
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
Oetjens et al. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records
EP2792754A1 (en) Biomarkers for epilepsy
Nathan et al. Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma
WO2005008555A1 (en) Computer-assisted means for providing personalised healthcare products
Ragoussis et al. Affymetrix GeneChip® system: moving from research to the clinic
Fan et al. Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population
EP1670942A2 (en) Genetic analysis for stratification of breast cancer risk
Loza et al. Association of alcohol-metabolizing genes with alcoholism in a Mexican Indian (Otomi) population
Pugach et al. The use of mouse models to investigate shear bond strength in amelogenesis imperfecta

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP